Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
San Francisco Examiner - July 27, 2006
Karl B. Hille, khille@baltimoreexaminer.com
Gaithersburg-based Panacos Pharmaceuticals is testing a drug called Bevirimat, which blocks the last step in the HIV life cycle - retarding its maturation after a new virus exits an infected cell.
"Resistance to currently approved drugs is probably the leading cause of treatment failure," Panacos CEO Graham Allaway, said.
According to the Centers for Disease Control and Prevention, 40,000 new HIV cases are diagnosed each year. As many as 80 percent of those in treatment for the disease have drug-resistant strains, and they appear in up to 25 percent of new cases.
In an infected person with no medical treatment, the disease produces as many as 10 billion copies of the virus each day, said Dr. Charles Davis, associate director of the Clinical Research Unit at the Institute of Human Virology. Simple reproductive mistakes can lead to mutations that thwart the mechanisms of drugs used to treat HIV.
He said the development of new drugs helps doctors and patients stay ahead of the virus.
Existing medications target the process by which HIV enters a human cell, creates copies of its own DNA and actually rewrites the cell's DNA, he said.
Bevirimat is the first drug to target the maturation stage after new copies of the virus leave the cell and before they develop the ability to infect a new cell, Allaway said.
Various studies already performed by Panacos have shown positive results. In tests on mice, scientists witnessed a reduction of virus replication by 90 percent. Also, scientists suspect the compound should not cause reactions with other drugs.
The drug is broken down differently by the liver than other AIDS drugs, Allaway said.
Bevirimat recently entered Phase 2 B clinical trials in June to evaluate safety and efficacy of the drug.
The current trial, working with fewer than 50 patients around the nation, is not accepting new participants, though future trials could incorporate hundreds of participants.
Researcher Justin Snow contributed to this report.
060727
SE060709
Copyright © 2006 - San Francisco Examiner. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Examiner, Permissions Desk, 110 Fifth Street, P.O. Box 7260, San Franciso, CA 94120.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .